This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Biogen compound BIO-32546 is a potent (IC50 = 1 nM), selective, oral, non-zinc-binding reversible autotaxin (ATX) inhibitor, and is…
molecule
2 years ago ●
1 min read
14. The Minoryx peroxisome proliferator-activated receptor gamma (PPARg) agonist, leriglitazone, is one of the several metabolites of pioglitazone, a member…
molecule
2 years ago ●
1 min read
The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for…
molecule
2 years ago ●
1 min read
The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib, is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated,…
molecule
2 years ago ●
2 mins read
The AstraZeneca ATR serine/threonine kinase inhibitor, ceralasertib (AZD6738), is a potent (1 nM biochemical IC50), orally bioavailable, ATP-competitive inhibitor, and is…
molecule
2 years ago ●
2 mins read
The Vincerx Pharma/Bayer CDK9 inhibitor, VIP152 (BAY 1251152), is a once-weekly (5-30 mg) IV agent in Ph. I for cancer with >50x…
molecule
2 years ago ●
1 min read
Load More
